Published in Cancer on August 01, 1983
Pathogenesis of follicular lymphoma. J Clin Invest (2012) 1.66
Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol (2007) 1.28
Transformation of follicular lymphoma. Best Pract Res Clin Haematol (2011) 1.27
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood (2013) 1.20
Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J Exp Med (1991) 1.12
Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol (1999) 0.93
Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant (2011) 0.92
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood (2014) 0.90
Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer (2014) 0.81
Use of percutaneous image-guided coaxial core-needle biopsy for diagnosis of intraabdominal lymphoma. Cancer Med (2014) 0.78
Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant (2014) 0.78
Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am J Pathol (2000) 0.78
Transformation of follicular lymphoma to double hit B-cell lymphoma causing hypercalcemia in a 69-year-old female: a case report and review of the literature. Case Rep Hematol (2014) 0.75
Transformation of follicular lymphoma in the retroperitoneal muscles demonstrated by CT-guided needle biopsy of FDG-avid lesions; case series. Int J Clin Exp Pathol (2013) 0.75
A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Cornell Scale for Depression in Dementia. Biol Psychiatry (1988) 6.61
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med (1976) 5.86
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
Two species of lysosomal organelles in cultured human fibroblasts. Cell (1979) 3.64
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89
A comparison of two phase I trial designs. Stat Med (1994) 2.71
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol (2001) 2.68
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med (1967) 2.38
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
The transport of lysosomal enzymes. J Supramol Struct (1977) 2.22
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Characterizing dye bias in microarray experiments. Bioinformatics (2005) 2.15
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Clinically defined vascular depression. Am J Psychiatry (1997) 2.06
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J (1995) 2.02
Staging laparotomy in early ovarian cancer. JAMA (1983) 2.02
The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02
TB testing. Vet Rec (1996) 2.01
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Strain and sex variation in the susceptibility to streptococcal cell wall-induced polyarthritis in the rat. Arthritis Rheum (1982) 2.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol (1989) 1.99
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry (1993) 1.92
Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med (1995) 1.91
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J (1994) 1.87
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Dominant negative guard cell K+ channel mutants reduce inward-rectifying K+ currents and light-induced stomatal opening in arabidopsis. Plant Physiol (2001) 1.82
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry (2000) 1.78
Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol (1972) 1.78
Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature (1973) 1.78
Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int (1984) 1.76
Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Immunohistochemical demonstration of IgG in Reed-Sternberg and other cells in Hodgkin's disease. J Exp Med (1974) 1.73
Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics (1999) 1.72
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med (1997) 1.70
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med (1975) 1.65
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med (1993) 1.64
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A (1993) 1.59
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem (1999) 1.57
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (1979) 1.55
Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg (1977) 1.55
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 1.55
Disability in geriatric depression. Am J Psychiatry (1996) 1.55
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat (1987) 1.54
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res (1993) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52